Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal,
immunologically mediated adverse drug reaction to unfractionated heparin or, less …

Bivalirudin, a direct thrombin inhibitor, is a useful alternative to heparin for anticoagulation in
infants and children. It has been found to be effective in patients requiring treatment of …

Heparin-induced thrombocytopenia (HIT) is a prothrombotic and potentially devastating
complication of heparin therapy due to formation of platelet-activating antibodies against …

The success in treatment of venous thromboembolism and acute coronary syndromes using
direct thrombin inhibitors has stimulated research aimed at finding a new anticoagulant from …

Thrombocytopenia and thromboembolism (s) may develop in heparin immune‐mediated
thrombocytopenia (HIT) patients after reexposure to heparin. At the Onassis Cardiac Surgery …

Patients with heparin-induced thrombocytopenia (HIT) that require anticoagulation for
cardiovascular procedures represent a challenging and high-risk group. Bivalirudin and …

Heparin resistance (unresponsiveness to heparin) is characterized by the inability to reach
acceptable activated clotting time values following a calculated dose of heparin. Up to 20 …

The development of novel anticoagulants requires a comprehensive investigational
approach that is capable of characterizing different aspects of antithrombotic activity. The …

Despite these advances, critical issues remain to be addressed. Future research efforts will
focus on the identification of novel clinical risk factors and biomarkers that will enable …

Heparin-induced thrombocytopenia is a well-recognized complication of anticoagulation
with heparin. We present the case of a patient with recent heparin-induced …